Author Archives: Yuhui "Neil" Ni

Allele Biotechnology Partners with CIRM to Accelerate Regenerative Medicine Product Development in California

Allele will provide CIRM grantees with priority access to Allele’s mRNA reprogrammed cGMP iPSC lines, mRNA technologies for reprogramming, differentiation, gene editing, and end-to-end cell therapy CDMO services.   Allele Biotechnology & Pharmaceuticals Inc. (ALLELE), a San Diego, CA, based biopharma and California Institute for Regenerative Medicine (CIRM) has signed a Memorandum of Understanding by…

Allele and K Pharma enter into licensing agreement to develop regenerative medicine products

Allele Biotechnology Inc. (ALLELE) in San Diego, California, and K Pharma Inc. (K Pharma; TSE: 4896) in Tokyo, Japan, have entered into a licensing agreement to develop regenerative medicine products. K Pharma was founded as a spinoff from Keio University School of Medicine by co-founders Drs. Komei Fukushima, Masaya Nakamura and Hideyuki Okano, the coming…

SCM and Allele: iPSC-based Diabetes Drug Development

SCM Lifescience to in-license iPSCs-based diabetes drug from U.S. firm – Pulse by Maeil Business News Korea July 02, 2021, Seoul SCM Lifescience has agreed to in-license a diabetes drug using pancreatic beta cells derived from induced pluripotent stem cells (iPSCs) from San Diego-based Allele Biotechnology and Pharmaceuticals, the South Korean stem cell therapy developer…

Allele cGMP iPSC Protocol Published in Current Protocols

Allele Discloses How its Highly Efficient iPSC Culturing is Conducted Under cGMP July 14, 2020 06:00 AM Eastern Daylight Time SAN DIEGO–(BUSINESS WIRE)–In their latest paper published in the online prepublication by the peer-reviewed journal Current Protocols, scientists and cGMP operation managers at Allele Biotechnology present a series of step-by-step protocols for manufacturers of iPSC (induced…